

DAFTAR PUSTAKA

1. Indonesian Rheumatology Association. Recommended Guidelines for the Diagnosis and Management of Gout. Jakarta: Indonesian Rheumatology Association; 2018. pp. 2-13
2. Lee JS, Kwon OC, Oh JS, et al. Clinical features and recurrent attacks in gout patients according to serum urate levels during an acute attack. *Korean Journal of Internal Medicine.* 2020;35(1):240–248. doi: 10.3904/kjim.2018.205
3. Kundu, A. K. Gout in 2017. *Rheumatology*, 2017. pp.180–181. http://apiindia.org/wpcontent/uploads/pdf/medicine_update_2017/mu_039.pdf
4. Bădulescu M, Macovei L, Rezuş E. Acute Gout Attack With Normal Serum Uric Acid Levels. University of Medicine and Pharmacy Grigore T. Popa-Iaşi Faculty of Medicine Department of Medical Specialties. 2014;118:942–945. PMID: 25581951
5. Goldsmith JS, & Report C. Normal Serum Uric Acid Levels During Acute Gout Attacks. Proceedings of UCLA Healthcare conference Volume 14. 2011 feb 3; Los Angeles, USA. 2010. pp. 1–4.
6. Min HK, & Kim HR. Does normouricemic status in acute gouty arthritis really reflect a normal status? Consider confounders of serum levels of urate.

- Korean Journal of Internal Medicine. 2020; 35(1):62–64. doi: [10.3904/kjim.2019.423](https://doi.org/10.3904/kjim.2019.423)
7. Wahyu Widyanto F. Arthritis Gout Dan Perkembangannya. *Saintika Medika*. 2017;10(2):145. doi: 10.22219/sm.v10i2.4182
 8. Ragab G, Elshahaly M, & Bardin T. Gout: An old disease in new perspective – A review. *Journal of Advanced Research*. 2017;8(5):495–511. doi: 10.1016/j.jare.2017.04.008
 9. Ema. (2020). (EMA) Guideline on clinical investigation of medicinal products for the treatment of gout. *GI*, 31(1), 12. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000425.jsp&mid=WC0b01ac0580034cf5
 10. Lin, Y. L. Clinical Practice Guidelines: Management of Gout (Second Edition). *Malaysia Health Technology Assessment Section (MaHTAS)*. 2021.
 11. Talbott, J. H. (2018). Diagnosis and treatment of gouty arthritis. *Postgraduate Medicine*, 5(5), 386–393. <https://doi.org/10.1080/00325481.1949.11693819>
 12. Hui, M., Carr, A., Cameron, S., Davenport, G., Doherty, M., Forrester, H., Jenkins, W., Jordan, K. M., Mallen, C. D., McDonald, T. M., Nuki, G., Pywell, A., Zhang, W., & Roddy, E. (2017). The British society for rheumatology guideline for the management of gout. *Rheumatology (United Kingdom)*, 56(7), 1056–1059. <https://doi.org/10.1093/rheumatology/kex150>
 13. FitzGerald, J. D., Dalbeth, N., Mikuls, T., et al. 2020 American College of

Rheumatology Guideline for the Management of Gout. *Arthritis Care and Research*, 2020;72(6), 744–760. <https://doi.org/10.1002/acr.24180>

14. Neilson, J., Bonnon, A., Dickson, A., & Roddy, E. Gout: diagnosis and management-summary of NICE guidance. *BMJ (Clinical Research Ed.)*, 2022;378, o1754. <https://doi.org/10.1136/bmj.o1754>
15. Dahanayake, C., Jordan, K. M., & Roddy, E. Crystal Clear. The 2022 NICE Guideline for the Diagnosis and Management of Gout. *Gout, Urate, and Crystal Deposition Disease*, 2023;1(1), 7–10. <https://doi.org/10.3390/gucdd1010002>
16. Pieterse E, Jeremic I, Czegley C, et al. Blood-borne phagocytes internalize urate microaggregates and prevent intravascular NETosis by urate crystals. *Nat Publ Gr*. 2016;(November):1–13. doi: 10.1038/srep38229.
17. Choi HK, Zhang Y, Dalbeth N. When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy. 2022;18(9):543–9. doi: 10.1038/s41584-022-00804-5
18. Ortiz-Urriarte M, Betancourt-Gaztambide J, Perez A, Roman YM. Urate-Lowering Therapy Use among US Adults with Gout and the Relationship between Patients' Gout Treatment Status and Associated Comorbidities. *Rheumato*. 2023;3(1):74–85. doi: 10.3390/rheumato3010006.